Form D · Biotechnology

Mitotherapeutix, LLC

Woodbridge, CT · CIK 0001657701

Offering snapshot reported May 22, 2025 · SEC filing

Reported sold: $2.97M
Investors reported: 5
Minimum accepted: $0
First sale: Dec 12, 2017

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$1,942,643 → $2,967,643

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
May 22, 2025	Amendment	$2,967,643	$1,025,000vs Feb 5, 2020	5	SEC filing
Feb 5, 2020	Amendment	$1,942,643	$1,000,000vs Dec 28, 2017	5	SEC filing
Dec 28, 2017	Initial	$942,643	No comparison	4	SEC filing
Oct 3, 2016	Initial	$30,000	No comparison	1	SEC filing

Offering details

Securities: Debt, Option to acquire, Security to be acquired
Exemptions: 06b
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-301888

Source: Form D, filed May 22, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Fenel Eloi	Director
Robert Hemley	Director, Executive
Robert Hennessey	Director, Executive
John V. Talley	Director, Executive
Daniel Wagner	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

4 Research Drive
Woodbridge, CT, 06525